1.84 USD
+0.03 (+1.66%)
1.84 USD
0 (0%)
DARE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. DARE may be in some trouble as it scores bad on both profitability and health. DARE has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year DARE has reported negative net income.
DARE had a positive operating cash flow in the past year.
In the past 5 years DARE always reported negative net income.
In the past 5 years DARE reported 4 times negative operating cash flow.
1.2 Ratios
DARE has a Return On Assets of -9.00%. This is in the better half of the industry: DARE outperforms 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DARE's Gross Margin of 108.60% is amongst the best of the industry. DARE outperforms 98.44% of its industry peers.
The Profit Margin and Operating Margin are not available for DARE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 108.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
DARE has more shares outstanding than it did 1 year ago.
DARE has less shares outstanding than it did 5 years ago.
DARE has a worse debt/assets ratio than last year.
2.2 Solvency
DARE has an Altman-Z score of -17.49. This is a bad value and indicates that DARE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DARE (-17.49) is worse than 82.29% of its industry peers.
DARE has a debt to FCF ratio of 1.20. This is a very positive value and a sign of high solvency as it would only need 1.20 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 1.20, DARE belongs to the best of the industry, outperforming 95.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.2 | ||
| Altman-Z | -17.49 |
ROIC/WACCN/A
WACC8.72%
2.3 Liquidity
DARE has a Current Ratio of 0.56. This is a bad value and indicates that DARE is not financially healthy enough and could expect problems in meeting its short term obligations.
DARE has a Current ratio of 0.56. This is amonst the worse of the industry: DARE underperforms 91.67% of its industry peers.
A Quick Ratio of 0.56 indicates that DARE may have some problems paying its short term obligations.
DARE has a worse Quick ratio (0.56) than 90.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.56 | ||
| Quick Ratio | 0.56 |
3. Growth
3.1 Past
DARE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -218.64%.
The Revenue for DARE has decreased by -99.65% in the past year. This is quite bad
EPS 1Y (TTM)-218.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.09%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 70.66% on average over the next years. This is a very strong growth
DARE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 188.14% yearly.
EPS Next Y-204.04%
EPS Next 2Y57.81%
EPS Next 3Y81.13%
EPS Next 5Y70.66%
Revenue Next Year-61.82%
Revenue Next 2Y392.65%
Revenue Next 3Y261.34%
Revenue Next 5Y188.14%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DARE. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 7.22, the valuation of DARE can be described as very cheap.
DARE's Price/Forward Earnings ratio is rather cheap when compared to the industry. DARE is cheaper than 94.27% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of DARE to the average of the S&P500 Index (36.59), we can say DARE is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.22 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, DARE is valued cheaply inside the industry as 97.40% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.12 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DARE's earnings are expected to grow with 81.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.81%
EPS Next 3Y81.13%
5. Dividend
5.1 Amount
DARE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.84
+0.03 (+1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.71%
Inst Owner Change13.05%
Ins Owners0.75%
Ins Owner Change0%
Market Cap26.29M
Revenue(TTM)9.80K
Net Income(TTM)-1.68M
Analysts82
Price Target10.97 (496.2%)
Short Float %1.86%
Short Ratio1.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2%
Min EPS beat(2)-19.49%
Max EPS beat(2)15.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.2%
Min Revenue beat(2)-104.71%
Max Revenue beat(2)-91.69%
Revenue beat(4)0
Avg Revenue beat(4)-99.03%
Min Revenue beat(4)-104.71%
Max Revenue beat(4)-91.69%
Revenue beat(8)1
Avg Revenue beat(8)-58.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)21.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-92.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.22 | ||
| P/S | 277.13 | ||
| P/FCF | 4.12 | ||
| P/OCF | 3.68 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.88
EYN/A
EPS(NY)0.26
Fwd EY13.86%
FCF(TTM)0.45
FCFY24.25%
OCF(TTM)0.5
OCFY27.16%
SpS0.01
BVpS-0.71
TBVpS-0.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 108.6% | ||
| FCFM | 6719.11% |
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 1.2 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 381.33% | ||
| Cap/Sales | 807.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.56 | ||
| Quick Ratio | 0.56 | ||
| Altman-Z | -17.49 |
F-Score3
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)1097.89%
Cap/Depr(5y)675.4%
Cap/Sales(3y)1956.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-218.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.09%
EPS Next Y-204.04%
EPS Next 2Y57.81%
EPS Next 3Y81.13%
EPS Next 5Y70.66%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-61.82%
Revenue Next 2Y392.65%
Revenue Next 3Y261.34%
Revenue Next 5Y188.14%
EBIT growth 1Y23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y127.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.8%
OCF growth 3YN/A
OCF growth 5YN/A
DARE BIOSCIENCE INC / DARE FAQ
Can you provide the ChartMill fundamental rating for DARE BIOSCIENCE INC?
ChartMill assigns a fundamental rating of 3 / 10 to DARE.
What is the valuation status of DARE BIOSCIENCE INC (DARE) stock?
ChartMill assigns a valuation rating of 5 / 10 to DARE BIOSCIENCE INC (DARE). This can be considered as Fairly Valued.
Can you provide the profitability details for DARE BIOSCIENCE INC?
DARE BIOSCIENCE INC (DARE) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for DARE stock?
The Earnings per Share (EPS) of DARE BIOSCIENCE INC (DARE) is expected to decline by -204.04% in the next year.